Login to Your Account



Deals And M&A NEWS

Five-year-old Leap Therapeutics Inc. stands to become a public company as the surviving entity in its merger with the Israeli biopharma, Macrocure Ltd., which will operate as a wholly owned subsidiary.

Beijing Shenogen Pharma Group Ltd. has signed a co-development deal with Lee's Pharmaceutical Holdings Ltd. to combine Shenogen's lead compound, icaritin, a traditional Chinese medicine-derived small-molecule drug, with Pexa-Vec, an oncolytic virus being developed in China by Lee's.

In January, after Eleven Biotherapeutics Inc. disclosed mixed phase III data in severe allergic conjunctivitis with the interleukin-1 signaling inhibitor EBI-005 – which also proved a dud in the late-stage experiment for dry eye disease in May 2015 – the stock took a 77 percent hit and Wall Street retreated.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: